Gore - search results
If you're not happy with the results, please do another search
“Valuable” 10-year data on the horizon for Gore’s GREAT registry
This advertorial, sponsored by Gore, is only available in selected countries and geographies.
In conversation with CX Vascular, Dennis Gable (The Heart Hospital Baylor...
Gore announces clinical study comparing VBX balloon expandable endoprosthesis to bare metal stents
Gore announced today the initiation of the Gore VBX FORWARD clinical study to compare the VBX stent graft to bare metal stenting for patients...
Gore announces first US enrolment for the Viafort vascular stent iliofemoral study
Gore has announced that the first US patient has been enrolled in a prospective, non-randomised, multicentre, single-arm study with five-year follow-up to evaluate the...
Five-year data on GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis “raise the bar” in aortoiliac...
This advertorial is sponsored by Gore.
At this year’s Charing Cross (CX) International Symposium (25–27 April, London, UK), Andrew Holden (Auckland City Hospital, Auckland, New...
First US patient enrolled in Gore Viafort vascular stent pivotal study
W L Gore & Associates (Gore) has announced that the first US patient has been enrolled in a prospective, non-randomised, multicentre, single-arm study with...
Gore initiates EMBRACE registry to evaluate VBX stent graft as bridging stent
W L Gore & Associates today announced that it is initiating the EMBRACE registry to capture real-world data about the Gore Viabahn VBX balloon...
Gore completes first-in-human implants of the Gore Viafort vascular stent
W L Gore & Associates (Gore) today announced the first implants of its investigational Gore Viafort vascular stent as part of the recently initiated...
Gore completes enrolment in the Gore Viabahn VBX balloon-expandable endoprosthesis EXPAND registry
W L Gore & Associates (Gore) has announced the completion of target enrolment in the EXPAND postmarket Registry of the Gore Viabahn VBX balloon-expandable...
Gore acquires InnAVasc Medical
Gore has announced the acquisition of InnAVasc Medical, a privately held medical technology company focused on advancing care for patients with end-stage renal disease...
Gore receives FDA approval of Gore Tag thoracic branch endoprosthesis for the repair of...
Gore recently announced that the US Food and Drug Administration (FDA) has approved the Gore Tag thoracic branch endoprosthesis (TBE) for the endovascular repair...
Gore’s lower profile delivery Viabahn endoprosthesis gets EMEA launch
Gore has announced the EMEA launch of the lower profile, large diameter Viabahn endoprosthesis with Propaten bioactive surface.
The device enhancements build on a market-leading...
Five-year results of the Gore Excluder IBE pivotal study confirm safety, efficacy and durability
W L Gore & Associates (Gore) has announced that five-year results from the US prospective, multicentre study (n=63) evaluating endovascular repair of iliac aneurysms...
GORE® ACTIVE CONTROL System: “A system for the masses”
NOTE: This video is ONLY available to watch in selected countries and geographies
Robert Rhee (New York, USA) moderates a Charing Cross 2021 webinar–A...
US physicians begin commercial use of the Gore Excluder conformable AAA endoprosthesis with Active...
Today, W L Gore & Associates (Gore) announced the first use of the US Food and Drug Administration (FDA)-approved Gore Excluder conformable abdominal aortic...
FDA approves Gore Excluder conformable AAA endoprosthesis with Active Control system
W L Gore & Associates (Gore) recently announced that the US Food and Drug Administration (FDA) has granted regulatory approval for the new Gore...
Bret Snyder named president and chief executive officer of W L Gore & Associates
W L Gore & Associates recently announced that Bret Snyder, chair of the Gore board of directors, will succeed Jason Field in the role...
Robert W Gore, chairman emeritus of W L Gore & Associates, dies at 83
Robert W “Bob” Gore, chair emeritus of the board of directors of W L Gore & Associates, passed away peacefully at home following a...
Gore enhances Viabahn endoprosthesis portfolio with lower profile delivery
Gore has announced the US launch of the lower profile, large diameter Gore Viabahn endoprosthesis.
Gore previously received approval from the US Food and Drug...
GORE®ACTIVE CONTROL System takes TEVAR to the next level with “convincing” results
The GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System was launched in the USA at the 2019 SVS Vascular Annual Meeting (VAM;...
First US patient receives Gore TAG conformable thoracic stent graft with ACTIVE CONTROL
Gore has announced the first US implant of its Gore TAG conformable thoracic stent graft with ACTIVE CONTROL system. The successful procedure was performed...
Gore receives FDA approval for the Gore TAG conformable thoracic stent graft with Active...
Gore has announced that the US Food and Drug Administration (FDA) has granted regulatory approval for commercial distribution for the Gore TAG Conformable Thoracic...
Gore Tigris vascular stent demonstrates high patency rates at 12 months
New results suggest that the Tigris vascular stent (Gore) is a safe and effective device that can be incorporated into a modern “leave-nothing-behind” treatment...
Gore introduces GORE TAG Conformable Thoracic Stent Graft with reduced profiles in Europe
Gore has introduced reduced profiles for the most commonly used diameters of the GORE TAG Conformable Thoracic Stent Graft with ACTIVE CONTROL System. The reduced profile...
First patient in Europe receives implant of Gore Excluder Conformable AAA Endoprosthesis with Active...
Gore has announced the first European patient implant of the Gore Excluder Conformable AAA Endoprosthesis with Active Control System. This next-generation endovascular aneurysm repair...
Gore announces successful patient implant of endovascular stent graft for the ascending aorta
Gore have announced the first implant in conjunction with the Gore ARISE study of the Gore Ascending Stent Graft, an investigational device and the...
Gore moulding and occlusion balloon for endovascular aortic repair receives approval in the USA,...
Gore has announced FDA 510(k) clearance, approval from the Japanese Ministry of Health, Labour, and Welfare, and receipt of CE mark for the innovative...
First commercial in-human use of Gore TAG Conformable Thoracic Stent Graft in Australia
The first patient has been implanted with the Gore TAG Conformable Thoracic Stent Graft with Active Control System after being included on the Australian...
First patient enrolled in investigational study of the Gore Excluder Conformable AAA endoprosthesis with...
Gore has announced the first implant of the Gore Excluder Conformable abdominal aortic aneurysms (AAA) endoprosthesis in the USA. The procedure took place on...
First patient enrolled in registry for the Gore TAG Conformable stent graft with Active...
Gore has announced the first patient enrolment in its post-market European registry for the Gore TAG Conformable Thoracic Stent Graft with Active Control System, following...
First-in-human use TEVAR of Gore TAG thoracic stent graft with Active Control system completed
Gore has announced the first patient implant of the TAG conformable thoracic stent graft with Active Control system after the receipt of CE mark...
Gore celebrates 20 years of experience in the aortic space
This year Gore is celebrating 20 years of experience and innovation in the aortic space. At the Charing Cross Symposium (25–28 April, London, UK)...
Gore receives regulatory approval for Excluder iliac branch endoprosthesis in Japan
Gore has received Shonin approval from the Japanese Ministry of Health, Labour and Welfare to market the Excluder iliac branch endoprosthesis (IBE), and is...
US FDA approves Gore Viabahn expandable stent graft for iliac artery use
The Gore Viabahn VBX balloon expandable endoprosthesis has received US Food & Drug Administration (FDA) approval for treatment of de novo or restenotic lesions found...
Gore joins vascular and endovascular leaders in recognising the 2016 Pioneers in Performance for...
Gore joined with leaders across the vascular and endovascular community in honouring five North American physicians as Pioneers in Performance. The biennial awards programme acknowledges...
VEITH 2016: Enrolment completed in Gore Global registry
At the 2016 VEITHsymposium (15–19 November, New York, USA), Gore announced that the completion of target enrolment in GREAT (Global registry for endovascular aortic...
New technology add-on payment awarded for Gore Excluder iliac branch endoprosthesis
The US Centers for Medicare and Medicaid Services (CMS) has granted the Gore Excluder iliac branch endoprosthesis (IBE) new technology status. Beginning on 1...
First implant completed in pivotal study of Gore TAG thoracic branch endoprosthesis
The first implant of Gore’s TAG thoracic branch endoprosthesis has been completed as part of the device’s pivotal study. The patient was enrolled by...
Gore Viabahn endoprosthesis celebrates 20 years since introduction
Gore is celebrating the 20th anniversary of the introduction of the Viabahn endoprosthesis; its stent graft for the treatment of complex peripheral vascular disease....
Gore DrySeal Flex introducer sheath now commercially available
Gore has announced the commercial availability of the Gore DrySeal Flex introducer sheath, after recently gaining clearance for use by regulatory bodies in the...
Gore Tigris vascular stent gains FDA approval for treatment of peripheral artery disease
Gore has announced US Food and Drug Administration (FDA) approval of the Gore Tigris vascular stent, a dual-component stent with a unique fluoropolymer/nitinol design....
CE mark granted to Gore Excluder conformable AAA prosthesis
Gore has received CE mark for its Excluder conformable abdominal aortic aneurysm (AAA) device, a product designed for the treatment of abdominal aortic aneurysms...
Gore Joins vascular and endovascular community in honouring 2016 Pioneers in Performance in Europe
Gore has joined with leaders across the vascular and endovascular community in honouring four European physicians as Pioneers in Performance at the 2016 Charing Cross...
Gore Excluder iliac branch endoprosthesis gains Health Canada approval
Health Canada has approved the Gore Excluder iliac branch endoprosthesis, making it the most recent off-the-shelf aortic branch device approved in Canada for the...
Gore Excluder iliac branch endoprosthesis granted FDA approval
The Gore Excluder iliac branch endoprosthesis has become the first off-the-shelf aortic branch to be approved by the US Food and Drug Administration (FDA)...
Gore launches new 7.5cm Viabahn endoprosthesis with heparin bioactive surface
Gore has announced the availability of a new 7.5cm length of the Viabahn endoprosthesis with heparin bioactive surface. The Viabahn endoprosthesis is now available in...
Over 250,000 patients treated with Gore Excluder abdominal aortic aneurysm endoprosthesis
More than 250,000 patients have been treated with the Gore Excluder abdominal aortic aneurysm (AAA) end prosthesis, the company has announced. This marks a...
Gore 2016 Pioneers in Performance Awards nominees announced
Gore has announced the nominees and opening of voting for the 2016 Pioneers in Performance Awards for North America. The announcement was made at...
Gore Excluder iliac branch endoprosthesis exceeds 1,000 implants worldwide
The Excluder iliac branch endoprosthesis has exceeded 1,000 implants worldwide; a milestone that comes two years after the device received the CE mark in...
Gore reaches 40 million implant milestone
In conjunction with the company’s 40th anniversary, Gore has announced that it has now sold 40 million devices worldwide. The milestone comes as the...
Gore praises Medicare announcement to reclassify endovascular abdominal aneurysm repairs
The decision comes after a two-year effort to improve the alignment of payment with cost of treatment for abdominal aortic aneurysms.
GORE TAG Thoracic Branch Endoprosthesis – Interview with Michael Dake
Colin Bicknell, London, UK, interviews Michael Dake, Stanford, USA, discussing the use of, and early results for, the new GORE TAG Thoracic Branch Endoprosthesis...
Gore Excluder iliac branch endoprosthesis registered in Australia and New Zealand
The first patient procedures in Australia were successfully completed by Steven Dubenec, head of Department of Vascular Surgery at Royal Prince Alfred Hospital, Sydney, and Jack Loa, at Macquarie University Hospital, Sydney.
Gore global registry for endovascular aortic treatment reaches 2,500 enrolled patients
A total of 5,000 consecutive patients from up to 300 worldwide sites will be enrolled in the registry and their treatment results will be tracked for 10 years.
Gore completes primary enrolment for the Excluder iliac branch clinical study
Sixty-two patients enrolled in US investigational device exemption clinical study to assess Excluder for managing common iliac artery aneurysms or aorto-iliac aneurysms.
Gore joins vascular and endovascular leaders in recognising Pioneers in Performance
Gore has joined with leaders across the vascular and endovascular community in honouring four North American physicians as 2014 Pioneers in Performance.
First patients enrolled in the Gore thoracoabdominal branched endoprosthesis study
Gore says that the device offers first and only complete off-the-shelf endovascular system specifically designed to treat aortic aneurysms involving visceral branch vessels.
Gore REVISE clinical study demonstrates superiority of Gore Viabahn endoprosthesis
The results of the REVISE clinical study showed that the Gore Viabahn endoprosthesis with Heparin Bioactive Surface is superior to percutaneous transluminal angioplasty - the current standard of care for treating stenoses or thrombotic occlusions.
First patient enrolled in Gore TAG Thoracic Branch Endoprosthesis LSA Feasibility study
Gore has announced that Himanshu Patel and David Williams, University of Michigan, USA, enrolled the first patient in the Gore TAG Thoracic Branch Endoprosthesis LSA Feasibility Study, a US-based, multicentre feasibility trial.
FDA approves Gore Viabahn endoprosthesis for revision of arteriovenous access
Gore has announced that the FDA has granted indication for the Gore Viabahn endoprosthesis to treat stenosis or thrombotic occlusion at the venous anastomosis of synthetic arteriovenous access grafts.
Gore C3 Delivery System approved in Japan
Gore has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare to market the Gore Excluder AAA Endoprosthesis featuring C3 Delivery System as a minimally invasive treatment for patients suffering from an abdominal aortic aneurysm.
Gore launches early cannulation capable Acuseal vascular graft
Designed for early cannulation within 24 hours after implantation, the Gore Acuseal vascular graft expands treatment options for earlier removal or possible avoidance of a central venous catheter.
First patient enrolled in Gore Excluder Iliac Branch Study
Endovascular specialists will enrol 60 patients at up to 50 sites during the course of this study. The first patient was treated by Brian Peterson in St Louis, USA.
Gore receives FDA approval for 25cm Viabahn endoprosthesis
The FDA has approved the 25cm Gore Viabahn endoprosthesis with heparin bioactive surface for the treatment of symptomatic peripheral arterial disease lesions in the superficial femoral artery.
Gore announces Pioneers in Performance winners for Latin America
Pierre Galvagni and Arno Von Ristow, from Brazil, Gustavo Rubio Arguello, from Mexico, and Alberto Munoz, from Colombia, are the first physicians practising in Latin America to be honoured with the award.
Improved Gore DrySeal sheath with hydrophilic coating is launched in Europe
The new Gore DrySeal sheath is designed to increase sheath lubricity with an advantage of minimising particulation of the hydrophilic coating.
Gore receives the CE mark for lower profile component for Excluder stent graft
The reduced profile allows the trunk-ipsilateral leg component to be used with an 18F DrySeal sheath and allows the 32mm aortic extender component to be used with a 17F compatible sheath.
Gore launches Q50 PLUS Stent Graft Balloon Catheter to treat abdominal aortic aneurysms
According to a company release, the new device features enhanced radial expansion force to aid in endograft modeling and sealing, and a new stopcock design to improve operator control.
Gore receives FDA approval for new Gore Excluder AAA Endoprosthesis components
The FDA has approved a new large diameter 35mm trunk-ipsilateral leg and 36mm aortic extender components, as well as the lower profile 31mm diameter trunk-ipsilateral leg and 32mm aortic extender components of the Gore Excluder AAA Endoprosthesis.
Gore introduces DrySeal Sheath with hydrophilic coating in the USA
The device allows for easier insertion and removal to and from blood vessels during endovascular repair and is designed to increase sheath lubricity and minimise particulation of the hydrophilic coating.
Gore receives the CE mark for a larger diameter version of the Gore Excluder...
Gore has received the CE mark for the new large diameter 35mm trunk-ipsilateral leg and 36mm aortic extender components of the Gore Excluder Abdominal Aortic Aneurysm Endoprosthesis, which is intended to be used in the treatment of infrarenal aortic neck diameters of up to 32mm.
Gore’s Pioneers in Performance USA winners honoured at the VEITHsymposium
Gore's Pioneers in Performance awards acknowledge exceptional work in the field of vascular and endovascular therapy, including aortic and lower-limb bypass and dialysis access surgery.
Gore Hybrid Vascular Graft available in 10cm configuration
The new configuration of this vascular graft used for replacement or bypass of diseased vessels, allows physicians to access even deeper vessels and create new access sites in anatomical locations that would have otherwise been abandoned.
Gore Hybrid Vascular Graft gets CE mark
The Gore Hybrid Vascular Graft (Gore) is indicated for use as a vascular prosthesis for replacement or bypass of diseased vessels impacted by aortic aneurysm, peripheral vascular and end stage renal disease.
SVS and Gore launch initiative to increase number of female vascular surgeons
The Society for Vascular Surgery (SVS) and Gore have announced an initiative that recognises the contributions of female vascular surgeons and aims to advance the number of women entering the profession.
Has the Gore C3 delivery system met the expectations for real life EVAR?
Paul Bachoo, Aberdeen, UK, spoke about his one-year experience with the Gore C3 system and presented an update on the GREAT Gore C3 registry data at the LINC conference in Germany.
New Gore Excluder endoprosthesis sizing options available
Gore has received FDA approval for the 23mm and 27mm diameter sizes of the contralateral leg component of the Gore Excluder endoprosthesis for treatment of abdominal aortic aneurysms.
First patients treated in Australia with Gore C3 delivery system for Gore Excluder AAA...
The first Australian procedures to treat patients with an abdominal aortic aneurysm using the new system were performed by Geoff White and Gavin O'Brien from Royal Prince Alfred Hospital, Camperdown and Marek Garbowski and Lorraine Corfield from Sir Charles Gairdner Hospital, Perth.
Gore reports first patient treated in the USA using Gore Viabahn Endoprosthesis with heparin...
The first procedure was performed by Tony Das, director of Peripheral Interventions, Texas Health Presbyterian Hospital Dallas, Texas, USA.
FDA approves the Gore Viabahn endoprosthesis to treat peripheral artery disease
The Gore Viabahn with heparin bioactive is the only stent-graft approved in the USA for use in the superficial femoral artery and iliac artery.
Gore receives CE mark for Gore Propaten Vascular Graft for haemodialysis access
The Gore graft utilises a unique covalent bonding technology to adhere heparin to the graft surface, known as Carmeda BioActive Surface (CBAS), which allows blood flowing through the graft to resist thrombosis or clotting.
Gore announces European availability of next generation of the Viabahn endoprosthesis
The reduced delivery profile will provide interventionalists with greater options for delivery with the same trackability and device performance in treating lower limb stenosis and occlusions.
First successful cases of patients treated using Gore C3 delivery system
The added deployment control of the Gore Excluder AAA repositions the future of endovascular repair for abdominal aortic aneurysm.
FDA approves Gore C3 delivery system for Gore Excluder AAA endoprosthesis
The added deployment control provides physicians increased confidence in treating challenging anatomies, as well as cannulation options.
Gore reaffirms commitment to stroke study, launches online resource
Cardiology and neurology investigators support continued study of patent foramen ovale (PFO) closure device.
Gore launches innovative delivery system for Gore Excluder AAA endoprosthesis in Europe
First clinical uses in Europe demonstrate new innovation enabling surgeons and interventionalists to reposition device for ideal placement while treating abdominal aortic aneurysms.
First Australian aortic aneursym patients treated with the Gore DrySeal Sheath
Revolutionary device delivers consistent performance, better control, and minimised blood loss during minimally invasive endovascular procedure.
New South Wales and Victoria Doctors first in Australia to treat AAA patients using...
Revolutionary Device Delivers Consistent Performance, Better Control, and Minimized Blood Loss During Minimally Invasive Endovascular Procedure.
Gore launches new cloud-based 3D case planning system
Revolutionary web-based tool powered by TeraRecon's Intuition application software was unveiled at 2010 Vascular Annual Meeting in Boston, USA.
Gore launches new “Ultimate SAAAVE” patient information site
The site is a part of the "Ultimate SAAAVE" Awareness Campaign that Gore sponsors in conjunction with the Society for Vascular Surgery (SVS).
Gore announces first human implants of the next generation Conformable Gore TAG Thoracic Endoprosthesis...
Gore has announced the first human implants of the next generation Conformable Gore TAG thoracic endoprosthesis in the United States for the treatment of traumatic transection of the thoracic aorta.
Gore receives CE mark approval for next generation Conformable Gore TAG Thoracic Endoprosthesis
The device is available in an expanded portfolio of sizes to meet a broad range of patient needs and was engineered to treat multiple etiologies.
Gore Flow Reversal System “safe and efficacious” for embolic protection during carotid angioplasty
Bernhard Reimers presented at EuroPCR the results from a prospective, non-randomised, European multicentre trial to evaluate the performance of the Gore flow reversal system.
Gore honours “Pioneers”
Manufacturer presents awards in recognition of the contribution made by endovascular "Pioneers"
Gore Flow Reversal System cleared by the FDA
Gore announced at the International Congress on Endovascular Interventions the clearance to market the technology that minimises the risk of emboli reaching the brain during critical stages of carotid artery stenting.
Modified version of the Gore TAG Thoracic Endoprosthesis receives FDA approval
Gore announced at the International Congress of Endovascular Interventions, in Arizona, US, that it has received approval from the FDA to market a modified version of the Gore TAG Thoracic Endoprosthesis for the treatment of thoracic aortic aneurysms.
Gore granted conditional approval for studies
The study will randomize patients to the GORE VIABAHN Endoprosthesis and to percutaneous transluminal angioplasty (PTA).
GORE PROPATEN vascular graft launched at VEITH
The GORE PROPATEN Vascular Graft is specifically designed for those vascular procedures in which the risk of acute graft thrombotic failure is of clinical concern.
EMPiRE study to assess GORE Neuro Protection System
..."The GORE Neuro Protection System is an important advancement in protecting patients during carotid artery stenting procedures"
Gore celebrates 30th birthday at Charing Cross
Gore's Medical Products Division will be celebrating their 30th anniversary at this year's Charing Cross Symposium
Vascular News 99 – September 2023
In this issue:
Paclitaxel-coated devices: US FDA removes red flag after review finds data do not support mortality risk
"A hugely exciting time": Experts...
Patient-centric innovation that stands the test of time
This advertorial is sponsored by Gore.
Even though it is celebrating its aortic portfolio reaching its 25-year milestone, Gore believes that this is only the...
Aortic device conformability: Adapting to the anatomy for better clinical outcomes
This advertorial is sponsored by Gore.
During a satellite symposia at the 2023 Charing Cross (CX) International Symposium (25–27 April, London, UK), speakers addressed the...
Study highlights need for “continuous comparative assessments” to guide endograft treatment decisions
A recent study comparing outcomes of endovascular aneurysm repair (EVAR) patients has reported no statistically significant differences in mortality or secondary rupture rates between...
Vascular News’ top 10 most popular stories of February 2023
February's top 10 includes the announcement that Abbott is to acquire Cardiovascular Systems, results of the PRESERVE study on the safety and effectiveness of...
Shockwave IVL: The last piece of the puzzle to overcome the challenge of hostile...
This article forms part of an educational supplement sponsored by Shockwave Medical. Explore the full Compliance is Key series here.
Giacomo Isernia and Gioele Simonte...
Vascular News’ top 10 most popular stories of January 2023
January's top 10 highlights an individual patient data meta-analysis on the safety of carotid endarterectomy in the elderly and a new randomised trial on...
Medtronic announces first enrolment in head-to-head global randomised trial evaluating durability of EVAR
Medtronic has announced the first patient enrolment in the ADVANCE trial, a head-to-head randomised controlled trial of two leading aortic stent graft systems, the...
Vascular News’ top 10 most popular stories of October 2022
Five-year outcomes from the randomised SPACE-2 trial on carotid artery stenosis, an interview with Joseph S Coselli, and a report on the "significant" increase...
BEST-CLI attracts US$3.3m funding injection to continue data analysis
The Novo Nordisk Foundation has made a US$3.3 million contribution toward the BEST-CLI (Best endovascular versus best surgical therapy in patients with critical limb...
Vascular News’ top 10 most popular stories of August 2022
The establishment of the first-ever global consensus for the appropriate use of intravascular ultrasound (IVUS) in lower extremity and arterial and venous interventions, results...
ESVS supports Ukrainian vascular surgery colleagues amidst ongoing crisis
Andriy Nykonenko and Pirkka Vikatmaa outline how the European Society for Vascular Surgery (ESVS) is helping vascular surgeons in Ukraine continue to provide medical...
Vascular News’ top 10 most popular stories of March 2022
A review of intraoperative adverse events in patients treated with fenestrated and branched endovascular aneurysm repair, meta-analysis findings on peripheral arterial disease symptoms in...
Viabahn use in claudicants with long, complex SFA lesions “safe and effective” through five...
Recently published research indicates that stent grafting with the Viabahn endoprosthesis (W L Gore & Associates) of long and complex superficial femoral artery (SFA)...
Type A dissection enters a new revolution
“We are at the beginning of a type A dissection revolution,” Joseph E Bavaria (University of Pennsylvania, Philadelphia, USA) told attendees at London Aorta...
Patients should get a choice between open and endovascular surgery for aortic conditions, CX...
A decisive vote at CX Aortic Vienna 2021 (5–7 October, broadcast) revealed that 90% of the audience was in favour of offering patients a...
Team at Copenhagen Aortic Center perform 150th E-nside implant, laud “valuable addition” to aortic...
This advertorial, sponsored by CryoLife, is only available in selected countries and geographies.
“The E-nside device is a valuable addition to our current...
CX 2021 Industry Partner On-demand Content
CX 2021 Industry Partner On-demand Content
Satellite Symposium: Innovative approaches to address Aortic and Fem-Pop procedural challenges
Moderator:
Ross Milner, Chicago, United StatesSatellite Symposium: Occlusive Iliac artery pathology:...
Real data and experience for below-the-knee bypass back heparin-bonded ePTFE as “the best alternative...
In a Gore-sponsored satellite symposium at the 2021 Charing Cross (CX) Digital Edition (19–22 April, online), Richard Neville (Falls Church, USA) and Walter Dorigo...
Real data and experience for below-the-knee bypass back heparin-bonded ePTFE as “the best alternative...
In a Gore-sponsored satellite symposium at the 2021 Charing Cross (CX) Digital Edition (19–22 April, online), Richard Neville (Falls Church, USA) and Walter Dorigo...
Viabahn balloon-expandable stent can successfully treat occlusive Iliac artery pathology, CX audience hears
In a Gore-sponsored Satellite Symposium at the Charing Cross Symposium (CX; 19–22 April, online), Michele Piazza (Padua, Italy) moderated a discussion on occlusive Iliac...
Great news for EVAR: Registry data shows procedure is safe, durable, and effective out...
Endovascular aortic repair (EVAR) is safe, durable, and effective, the five-year interim results of the Global Registry for Endovascular Aortic Treatment (the GREAT registry)...
“From pioneering times to a mature technology”: The evolution of bridging stents for FEVAR...
There are several covered stents on the market that are used in an off-label setting as bridging stents for fenestrated and branched endovascular aneurysm...
Complications of EVAR in 2020: Are they lower than they were a decade ago?
Mo Hamady discusses developments in aortic stent grafts in recent years, and offers a contemplation on the complications associated with endovascular aneurysm repair (EVAR)....
CX 2020 LIVE: Surgeon-modified and custom-made endografts carve their place in juxtarenal aneurysm treatment
During the last five weeks, CX 2020 LIVE has attracted over 6,000 registrants from more than 120 countries. The topic of the 10th and final session was...
CX 2020 LIVE: Vascular Access session showcases new technologies, while debate on place of...
The CX 2020 LIVE Vascular Access Consensus session sparked global interest, with chair Nick Inston (Birmingham, UK) and moderator Domenico Valenti (London, UK) taking...
CX 2020 LIVE: Strong support for relining peripheral arteries and rivaroxaban use for widespread atherosclerosis
In a series of Podium 1st presentations from world-class faculty, CX 2020 LIVE attendees heard the latest data on peripheral arterial disease management and an evaluation of different types of stents, including...
CX 2020 LIVE aortic arch discussion highlights importance of underlying pathology and benefit of...
Last week, the CX 2020 LIVE agenda turned to the technically challenging topic of aortic arch interventions. Through presentations, discussion, and polling, the session—chaired...
Innovative solutions for the treatment of complex aorto-iliac occlusive disease
In this supplement, sponsored by Gore:
Michele Antonello considers the complexity of aorto-iliac occlusive disease, treatment gaps and current options
Jean Bismuth discusses results...
Preliminary experience with LSA branched devices shows promising results
Preliminary experience with left subclavian artery (LSA) branched devices indicates low morbidity and stroke rates with high patency rates. This was the conclusion of...
CX 2019: VBX set to be a “game-changer” for treating complex aortic aneurysms
𝙏𝙝𝙞𝙨 𝙫𝙞𝙙𝙚𝙤 𝙞𝙨 𝙞𝙣𝙩𝙚𝙣𝙙𝙚𝙙 𝙛𝙤𝙧 𝙝𝙚𝙖𝙡𝙩𝙝𝙘𝙖𝙧𝙚 𝙥𝙧𝙤𝙛𝙚𝙨𝙨𝙞𝙤𝙣𝙖𝙡𝙨 𝙞𝙣 𝙀𝙪𝙧𝙤𝙥𝙚 𝙤𝙣𝙡𝙮.
Giovanni Torsello (Münster, Germany) and Mauro Gargiulo (Bologna, Italy) discuss the “very high” morbidity and...
Virtual reality stimulates discussion at CX
For the first time, the audience at the 2019 Charing Cross Symposium (London, UK) was able to experience an array of virtual reality live...
EVAR with an iliac branch endoprothesis is safe and effective
On Wednesday, during the Aortic Podium 1st session at Charing Cross (CX) Symposium, Fabio Verzini (Turin, Italy) reported that endovascular aneurysm repair (EVAR) with...
GREAT study to shed light on long-term outcomes of aortic repair
Ross Milner (Chicago, USA) spoke to Vascular News at the VEITHsymposium about the importance of long-term data for aortic endografts and the GREAT (Global...
Outcomes of the ANCHOR registry show consistent outcomes for endoanchors at three years
Real-world outcomes in patients from the ANCHOR registry at three years show safe and effective performance of the Heli-FX EndoAnchor system (Medtronic) in complex...
STEP seeks to advance patient safety after TEVAR
Stroke is a major concern following TEVAR (thoracic endovascular aortic repair) and Charing Cross delegates heard the results from a collaborative study that pooled...
Two-year data from Viabahn BX IDE trial “promising”
The 24-month data from the Viabahn BX Flex balloon-expandable stent (Gore) investigational device exemption (IDE) trial are “promising” with sustained clinical and patency benefits...
The use of embolic filters to reduce the stroke risk in TEVAR
Richard Gibbs and colleagues have previously demonstrated that 80% of patients undergoing thoracic endovascular aneurysm repair (TEVAR) have evidence of new post-procedural cerebral infarcts by comparing pre-...
Excluder Iliac Branch Endoprosthesis device meets mid-term primary endpoints in clinical trial and real-world...
At the 2017 Vascular Annual Meeting (VAM; 30 May–3 June, San Diego, USA), mid-term follow-up data from a pivotal trial (IBE 12-04) of the...
The relationship between aortic arch interventions and acute stroke
At the 2017 Charing Cross Symposium (25–28 April, London, UK), speakers and panellists discussed the challenges of endovascular aortic arch procedures and their potential...
Watch and learn: CX Aortic Edited Cases
Tuesday’s CX Aortic Edited Cases session featured exciting and engaging standing-room only case presentations, including Andrew Holden’s (Auckland, New Zealand) first-in-man implantation of the...
Mounting evidence supports increasing use of parallel graft endovascular techniques for select complex aortic...
In a 15-year evolution, parallel graft techniques have emerged as part of the effort to rescue or preserve excluded aortic branches in the context...
Next-generation stent systems for lower extremity arterial occlusive lesions
Balloon angioplasty has been utilised in lower extremity revascularisation procedures since the 1970s, but the durability of this technique is limited by both mechanical...
Tigris stent gets Health Canada approval for peripheral artery disease
Gore has announced the Health Canada approval of the Tigris vascular stent, a dual-component stent with a unique fluoropolymer/nitinol design. The device, which gained...
Endovascular treatment in the aortic arch
The development of endovascular stent grafts in the descending aorta has significantly reduced the number of open surgical repairs being performed. However, the ascending...
First implant of Viabahn VBX stent graft completed
Houston Methodist Hospital has become the first US institution to implant the newly FDA-approved Viabahn VBX balloon expandable endoprosthesis (VBX stent graft; Gore), to...
Acute Dissections Symposium: “The Great Masquerader”
The best management of type B aortic dissection is an ongoing debate. In April 2016, W. L. Gore & Associates held a two-day symposium...
TIGRIS trial finds no stent fractures and positive primary patency in long lesions at...
Twenty-four month TIGRIS trial follow-up data show that treatment using the Tigris nitinol stent (Gore) for long lesions in the superficial femoral and popliteal...
New developments in dialysis grafts
With the rising incidence of haemodialysis worldwide, there is an ever-increasing need for creative, durable means of access. The National Kidney Foundation and Centers...
One-year Japanese results support use of the Viabahn endoprosthesis to treat complex SFA disease
Gore has announced positive results from a prospective, multicentre investigational device exemption (IDE) clinical study of the Viabahn endoprosthesis with heparin bioactive surface in...
Iliac branch device results show value of internal iliac artery revascularisation
The new Excluder iliac branch endoprosthesis (Gore) is safe and effective at treating aortoiliac aneurysms and common iliac artery aneurysms, maintaining blood flow into...
Total endovascular repair of zone 2 aortic arch aneurysms can be achieved with a...
One-year outcomes of a prospective, non-randomised, feasibility trial evaluating the treatment of aneurysms involving the proximal descending thoracic aorta indicate that total repair can...
Viabahn found to provide superior patency and reduced interventions versus angioplasty alone for challenging...
Gore announced on 28 June 2016 the publication of clinical study results from the Gore REVISE Clinical Study* in the Journal of Vascular Surgery...
TAG TEVAR family reaches 100,000 device distribution milestone
Gore has announced that its TAG thoracic device family has exceeded 100,000 devices distributed worldwide.
The conformable TAG device is indicated in most geographical regions...
Final subject enrolled in Excluder thoracoabdominal branch endoprosthesis early feasibility study
Enrolment into Gore’s early feasibility study evaluating the Excluder thoracoabdominal branch endoprosthesis (TAMBE) for the treatment of aortic aneurysms involving the visceral branch vessels...
Nominees announced for 2016–2017 Pioneers in Performance Awards for Latin America
The nominees and opening of voting for 2016-2017 Pioneers in Performance Awards for Latin America has been announced at the Congreso Internacional Cirugia Endovascular...
First implant completed in thoracoabdominal aortic aneurysm clinical study
The first US implant of the Gore Excluder thoracoabdominal branch endoprosthesis has taken place during a clinical study of the treatment of aortic aneurysms...
First patients enrolled in the RELINE MAX Viabahn clinical study
The first patients are now enrolled in the Gore RELINE MAX clinical study, a post-approval study to continue to evaluate the Viabahn endoprosthesis with...
PERICLES study helps bring chimney technique “out of the shadows”
Konstantinos P Donas (Münster, Germany) claims that the “widespread scepticism” over the safety and efficacy of endovascular aortic aneurysm repair (EVAR) procedures using the...
PERICLES study helps bring chimney technique “out of the shadows”
Konstantinos P Donas claims that the "widespread scepticism" over the safety and efficacy of EVAR procedures using the chimney technique is probably not justified after the largest collection of data for the strategy indicated that it was a safe and effective alternative endovascular approach for pararenal aortic pathologies.
When and how to use chemical and mechanical barriers for in-stent restenosis
In-stent restenosis patients with severe claudication or critical limb ischaemia should be treated with drug-coated technologies if they present with focal lesions and with...
“Preserving pelvic artery perfusion should be a goal during EVAR”
Early experience with the new Iliac Branch Excluder shows that the endograft is safe and effective, with a high success rate and patency of over 90% at six months.
Excluder conformable abdominal aortic aneurysm endoprosthesis receives approval for clinical study in the USA...
The device is designed to bring endovascular therapy options to patients who were previously considered to be untreatable.
Global vascular thought leaders document shift toward individualising patient care in surgical bypass
Gore is making available an educational compendium of presentations and discussions from the inaugural Gore-sponsored Surgical Bypass Summit to promote knowledge sharing around this topic.
FDA approves endovascular treatment of in-stent restenosis with Viabahn endoprosthesis
Now indicated for the treatment of failed bare metal stents in the superficial femoral artery, the Viabahn device has more vascular indications supported by more level 1 clinical trials than any other self-expanding peripheral stent or stent-graft.
High patency rates with early cannulation graft with bioactive surface
Results of vascular access using a new ePTFE graft show "satisfactory" primary patency rates at one year, and are similar to those achieved with an autogenous access. In the experience, conducted in one centre in Italy, the graft also demonstrated a low thrombosis rate.
Andrew Holden
Andrew Holden, associate professor of Radiology, Auckland University School of Medicine, Auckland, New Zealand, has been involved in the investigation of several endovascular devices...
Nominees announced for 2014 Pioneers in Performance North America
The physicians have been nominated by their peers for their dedication to advancing vascular and endovascular therapy and minimally invasive treatment options for patients worldwide.
Drug-eluting devices for the superficial femoral artery–why and when to treat?
While a large number of physicians are now convinced that drug elution represents a step forward from angioplasty and bare metal stenting in the...
Excluder iliac branch endoprosthesis receives the CE mark
The first patient procedures with the system in Europe were successfully completed by vascular surgeons Piergiorgio Cao, Rome, Italy, Mo Hamady, London, UK, and Michael Jenkins, London, UK.
Heparin-bonded endoprosthesis shows promising results in long femoropopliteal lesions
One-year results of the VIASTAR trial published online in the Journal of the American College of Cardiology suggest that a heparin-bonded covered stent may be superior to bare metal stents in the treatment of long femoropopliteal artery disease.
Thoracic-length Heli-FX aortic securement system receives the CE mark
Similar to the system that was cleared in May 2011 and designed for treating abdominal aortic aneurysms, the new system consists of a longer delivery device with additional tip configurations to bring the helical EndoAnchor technology to the treatment of thoracic aneurysms.
FDA clears HeliFX Aortic Securement System for thoracic endovascular aneurysm repair
Similar to the original HeliFX system (Aptus Endosystems) that was cleared in November 2011 and designed for treating abdominal aortic aneurysms, the new system consists of a longer delivery device with additional tip configurations for the treatment of thoracic aortic aneurysms.
Aptus Endosystems initiates the ANCHOR post-market registry
ANCHOR is a global, multicentre, prospective post-market registry, which will evaluate the use of the HeliFX Aortic Securement System (Aptus Endosystems) in the treatment of abdominal aortic aneurysms.
FDA expands use of endovascular graft to treat aortic tears
The TAG Thoracic Endoprosthesis (Gore) is the first endovascular graft approved by the FDA to treat a variety of thoracic lesions, including aneurysms as well as thoracic aortic transections.
Will long-term trial results boost endovascular treatment in the SFA?
New data from four studies released recently show promising results for stents and stent grafts in the superficial femoral artery.
Aptus receives FDA clearance for EndoStapling system
The HeliFX system from Aptus Endosystems provides physicians with a novel technology to repair endovascular grafts that have migrated away from the implant site, have developed endoleaks or are at risk of developing these complications, which are commonly seen after EVAR.
Is current carotid stent design inadequate?
At CX33, there was a debate on the motion "Current carotid stent design is inadequate and contributes significantly to procedure-related stroke." Sumaira Macdonald, Newcastle, UK, spoke for the motion and William Gray, New York, USA, against.
First Acuseal vascular graft is implanted in Europe
A new early cannulation graft for haemodialysis access has been implanted for the first time in Europe on 13 May 2011. The procedure with the Gore Acuseal was carried out at St George's Hospital, London, UK, by renal surgeon, Eric Chemla.
Nominees announced for 2011 Pioneers in Performance Awards for Europe
Awards programme, sponsored by Gore, honors medical specialists advancing therapy and improving patient and clinical performance through active collaboration. Online voting opens at www.PioneersInPerformance.com
Vascular and endovascular leaders honoured as 2010 Pioneers in Performance
Gore joined with leaders from across the vascular and endovascular community to honour a distinguished group of eight physicians receiving the annual recognition.
CE mark for longer length Viabahn
Gore's 25cm Viabahn is the longest ever length stent graft.
Europe set for wave of next generation EVAR devices
Endurant, Zenith LP, Excluder C3 and Incraft amongst devices that expand the stent graft market.
Jan Blankensteijn
Jan Blankensteijn, Division of Vascular Surgery, VU Medical Center, Amsterdam, The Netherlands, and principal investigator of the DREAM trial, has EVAR as his first...
Covered stents do the trick in long TASC C and D lesions
In recent years, the implantation of covered stents has emerged as a strategy for the treatment of occlusions in the superficial femoral artery. In several smaller studies, covered stenting of the superficial femoral artery has shown superior patency at two years after intervention.
FDA approval for larger diameter, small profile endoprosthesis
US regulator approves 31mm version of the Gore Excluder for the treatment of abdominal aortic aneurysm
New products at CX 31
A range of new products for the treatment of vascular disease will be launched and showcased at the CX Symposium. Aorfix (Lombard), Lifestent (Bard), Viabahn (Gore), IN.PACT (Invatec), and VenaCure EVLT (Angiodynamics) are some of the innovations available in the industry area.
Michel Makaroun
Vascular News talks to Dr Michel Makaroun, Professor of Surgery, University of Pittsburgh School of Medicine, Chief, Division of Vascular Surgery,...
Thoracic dissections studies updated at the VEITH
INSTEAD and IRAD - What have we learned?
The preliminary conclusion of the INSTEAD study, presented by Dr Christoph Nienaber, Germany, is that...
The Great Debates at CX
Charing Cross is famous for its 'Great Debates'
Thoracic challenges: dissection and aneurysms
Each year 50,000 patients are diagnosed with lesions of the thoracic aorta in Europe
Quo Vadis endovascular abdominal aortic aneurysm repair?
Editorial: Roger Greenhalgh
CX 30th ‘Vascular and Endovascular Consensus Update’
The 30th Charing Cross International Symposium will take place at Imperial College, London, UK, from April 12th to 15th 2008.
Boost for stenting in the SFA
The results from three studies revealed that stenting is a safe and effective treatment option for treating SFA lesions
Cook reveals aneurysm market results for 2006
Barry Thomas from Cook Medical's Aortic Intervention Division, presented an overview of the global market events relating to abdominal aortic aneurysm (AAA) stent grafts.
Symptomatic patients should be treated with closed cell stents
Dr Marc Bosiers discusses whether device characteristics affect outcomes in carotid artery stenting
EVC 2006: Expanding endovascular indications
At this year's meeting were many challenging questions including - what evidence is there for endovascular treatment'?
MasterClass discusses the management of thoracic aortic disease
The event was again organised by Peter Taylor and John Reidy of Guy's and St Thomas' NHS Foundation Trust, London, UK.
Study to assess stenting vs medical treatment in acute Type B dissections
Study investigates mortality and the re-intervention rate due to dissection related disease
Lifeline challenges EVAR 2 outcomes
AHRQ Review
Aortic Summit: At the peak of endografting
Gore Aortic Summit
Rebranching of renals at CX
Gore's Satellite Symposium
Towards Vascular and Endovascular Consensus
at Charing Cross
EUROSTAR Registry hailed at ESVS
Guest speakers concluded that the Registry had provided the vascular community with many valuable lessons
Thoracic aortic dissection at 2005 Thoracic Masterclass
Vascular News attended the recent Masterclass V
US Thoracic Market set to explode
At the moment the market for Thoracic grafts appears ready to expand significantly in the US
Towards Vascular and Endovascular Consensus at Charing Cross
Over 1,500 people from 60 countries attended the 27th Charing Cross International Symposium
Protect the patients not the procedure
At the International Congress XVIII on Endovascular Interventions in Phoenix, Arizona
Profile: Ken Ouriel
Vascular News talks to Dr Kenneth Ouriel
Medtronic launches Valiant Thoracic Stent Graft at CX Symposium
This year's CX Symposium will see the introduction of Medtronic's innovative thoracic endograft device, the Valiant Thoracic Stent Graft with Xcelerant Delivery System.
Charing Cross goes from strength to strength
Last year's Charing Cross International Symposium reached new heights
Big push to get SAAAVE Bill passed
Screen Abdominal Aortic Aneurysms Very Efficiently
The 7th International Symposium on Critical Issues in Endovascular Grafting
The most important European meeting of the year for aortic endografting
